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Cell-based cardiac repair represents a promising therapeutic approach to treat heart 
failure. Among various cell types, skeletal myoblast (SkM) has been extensively used 
for cardiac cell therapy due to its myogenic potential, proliferative capacity, 
resistance to ischemia, and non-tumorigenic nature. The present study was to 
investigate the characteristics of human SkMs in vitro and in vivo, to investigate and 
compare immune responses, SkM survival profile, and SkM transplantation efficacy 
following xenogeneic, allogeneic, and autologous transplantation of SkMs in a rat 
myocardial infarction model. 
By immunostaining and cell counting, we showed that immunocytes infiltrated 
severely in the early stage (from day-1 to day-7) after SkM transplantation. 
Macrophages and CD8+ lymphocytes infiltrated from day-1; CD4+ lymphocytes 
infiltrated from day-4, but all immunocytes subsided by day-28. By immunostaining, 
real time PCR, and β-gal assay, we confirmed and quantified the survival of SkMs. 
After transplantation, the majority of the SkM signals were rapidly lost by day-1.  
After day-1, a gradual increase in the number of SkMs was observed until 4 weeks 
after cell transplantation, resulting from the SkM proliferation out-balancing the 
gradual loss. One interesting finding of our study is that the grafted human SkMs and 
rat SkMs survive and differentiate well in the immunocompotent hosts even without 
any immunosuppression. From this we suggest that SkMs enjoy a non-autologous 
graft acceptance in myocardium, a finding which may have far reaching implications 
in clinical perspective. In addition, we demonstrated that there was a close correlation 
between immunocyte number and SkM total number.   
In all SkM transplantation groups, SkM transplantation improved the heart 
performance by increasing the contraction function (ejection function) and limiting 
the ventricular dilation (left ventricular end diastolic diameter). Furthermore, we 
demonstrated that there was a linear relationship between the SkM survival and 
ventricular function as well. In our study, cyclosporine inhibited infiltration of the 
immune cells, enhanced the survival of transplanted SkMs and improved heart 
performance. Even in autologous groups, cyclosporine does enhance the heart 
performance.  
This study enabled us a better understanding of the early cellular behavior of SkMs, 
especially human SkMs, and the underlying mechanisms that govern early graft 
attrition in SkM transplantation. The present study also suggests a feasibility of non-






ABCG2+     ATP-binding cassette transporter  
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